Key Points
- CEO insider sale: CEO Amy Burroughs sold 14,583 shares on Feb. 17 at an average of $39.19 for proceeds of $571,507.77, trimming her position by 4.8% to 288,976 shares valued at about $11.3 million.
- Heavy institutional ownership: Hedge funds and institutional investors own roughly 98.26% of TERN, with several firms (Vestal Point, Janus Henderson, Capitolis, Commodore, Lord Abbett) establishing large stakes worth collectively in the hundreds of millions.
- Positive analyst outlook: The consensus rating is "Moderate Buy" with an average price target of $58.11 and multiple recent upgrades and higher targets (e.g., HC Wainwright $60, Barclays $56, Leerink $58).
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CEO Amy Burroughs sold 14,583 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $39.19, for a total transaction of $571,507.77. Following the transaction, the chief executive officer owned 288,976 shares of the company's stock, valued at $11,324,969.44. This trade represents a 4.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Terns Pharmaceuticals Stock Down 0.6%
Terns Pharmaceuticals stock opened at $39.35 on Thursday. The company's 50-day moving average price is $38.52 and its 200-day moving average price is $21.95. The company has a market cap of $4.08 billion, a PE ratio of -38.20 and a beta of -0.28. Terns Pharmaceuticals, Inc. has a twelve month low of $1.87 and a twelve month high of $48.26.
Hedge Funds Weigh In On Terns Pharmaceuticals
Institutional investors have recently modified their holdings of the stock. Commodore Capital LP purchased a new stake in shares of Terns Pharmaceuticals in the third quarter valued at approximately $42,807,000. Vestal Point Capital LP purchased a new stake in shares of Terns Pharmaceuticals in the 4th quarter worth $181,800,000. Janus Henderson Group PLC bought a new position in shares of Terns Pharmaceuticals during the 4th quarter worth $136,496,000. Capitolis Liquid Global Markets LLC purchased a new position in shares of Terns Pharmaceuticals during the fourth quarter valued at $123,026,000. Finally, Lord Abbett & CO. LLC bought a new stake in shares of Terns Pharmaceuticals in the fourth quarter valued at about $109,581,000. 98.26% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on TERN. William Blair upgraded Terns Pharmaceuticals from a "market perform" rating to an "outperform" rating in a report on Monday, November 3rd. UBS Group upgraded shares of Terns Pharmaceuticals to a "strong-buy" rating in a report on Thursday, December 4th. Leerink Partners began coverage on shares of Terns Pharmaceuticals in a research note on Monday, February 9th. They set an "outperform" rating and a $58.00 price target for the company. Barclays increased their price objective on shares of Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 9th. Finally, HC Wainwright boosted their target price on Terns Pharmaceuticals from $20.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Terns Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $58.11.
Check Out Our Latest Stock Analysis on Terns Pharmaceuticals
About Terns Pharmaceuticals
(
Get Free Report)
Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.
The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
